LV12018B - PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS - Google Patents

PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS Download PDF

Info

Publication number
LV12018B
LV12018B LVP-97-163A LV970163A LV12018B LV 12018 B LV12018 B LV 12018B LV 970163 A LV970163 A LV 970163A LV 12018 B LV12018 B LV 12018B
Authority
LV
Latvia
Prior art keywords
olanzapine
less
methyl
active ingredient
quot
Prior art date
Application number
LVP-97-163A
Other languages
English (en)
Latvian (lv)
Other versions
LV12018A (lv
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12018(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of LV12018A publication Critical patent/LV12018A/xx
Publication of LV12018B publication Critical patent/LV12018B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
LVP-97-163A 1995-03-24 1997-09-08 PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS LV12018B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
LV12018A LV12018A (lv) 1998-04-20
LV12018B true LV12018B (en) 1998-09-20

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-163A LV12018B (en) 1995-03-24 1997-09-08 PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS

Country Status (49)

Country Link
US (1) US5736541A (es)
EP (3) EP0733635B1 (es)
JP (1) JPH11502535A (es)
KR (1) KR100399688B1 (es)
CN (1) CN1065536C (es)
AP (1) AP828A (es)
AR (2) AR010448A1 (es)
AT (4) ATE331719T1 (es)
AU (1) AU706471B2 (es)
BG (1) BG62619B1 (es)
BR (1) BR9607790A (es)
CA (1) CA2214005C (es)
CH (1) CH690579A5 (es)
CO (1) CO4650278A1 (es)
CZ (1) CZ292688B6 (es)
DE (4) DE69630324T2 (es)
DK (4) DK1445259T3 (es)
EA (1) EA000149B1 (es)
EE (1) EE03489B1 (es)
EG (1) EG23659A (es)
ES (3) ES2266719T3 (es)
FI (1) FI973750A0 (es)
GB (1) GB2313835B (es)
HK (1) HK1013988A1 (es)
HU (1) HU224989B1 (es)
IL (1) IL117610A (es)
IS (1) IS1896B (es)
LT (1) LT4349B (es)
LU (1) LU90096B1 (es)
LV (1) LV12018B (es)
MY (1) MY114701A (es)
NO (1) NO314663B1 (es)
NZ (1) NZ306110A (es)
OA (1) OA10510A (es)
PA (1) PA8353701A1 (es)
PE (1) PE44897A1 (es)
PL (1) PL183723B1 (es)
PT (3) PT1095941E (es)
RO (1) RO118872B1 (es)
SE (1) SE9703205D0 (es)
SI (4) SI0733635T1 (es)
SK (1) SK284143B6 (es)
SV (1) SV1996000031A (es)
TR (1) TR199701017T1 (es)
TW (2) TW513432B (es)
UA (1) UA44765C2 (es)
WO (1) WO1996030375A1 (es)
YU (1) YU49478B (es)
ZA (2) ZA962342B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EP0852496A4 (en) * 1995-09-29 1998-11-11 Lilly Co Eli METHOD FOR TREATING CHRONIC ICT
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
US6258807B1 (en) * 1996-03-25 2001-07-10 Eli Lilly And Company Method for treating pain
WO1997035582A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
AU725556B2 (en) * 1996-03-25 2000-10-12 Eli Lilly And Company Method for treating pain
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998011893A1 (en) * 1996-09-23 1998-03-26 Eli Lilly And Company Olanzapine dihydrate d
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
ID29574A (id) * 1998-09-30 2001-09-06 Lilly Co Eli Formulasi 2-metil-tieno-benzodiazepin
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
CA2420987A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
EP1470130A2 (en) * 2001-12-24 2004-10-27 Sun Pharmaceuticals Industries Ltd. Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno 2,3-b 1,5 benzodiazepine
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) * 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
DE602004014264D1 (de) * 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
DE112005000641T5 (de) * 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
AR053562A1 (es) * 2005-03-21 2007-05-09 Reddys Lab Ltd Dr Proceso para la preparacion de la forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
US20140057303A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
NO305125B1 (no) * 1992-05-29 1999-04-06 Lilly Industries Ltd Farmas°ytiske forbindelser
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
EA199700262A1 (ru) 1998-02-26
LV12018A (lv) 1998-04-20
ATE251627T1 (de) 2003-10-15
DE69614426T2 (de) 2002-05-23
YU17796A (sh) 1999-03-04
SE9703205L (sv) 1997-09-05
CH690579A5 (de) 2000-10-31
EG23659A (en) 2007-03-26
TW513432B (en) 2002-12-11
DE69636313D1 (de) 2006-08-10
EP1095941B1 (en) 2003-10-08
EP1445259A1 (en) 2004-08-11
CN1179160A (zh) 1998-04-15
PT733635E (pt) 2001-12-28
BG101900A (en) 1999-03-31
KR100399688B1 (ko) 2004-02-18
HUP9802824A3 (en) 2000-01-28
HUP9802824A2 (hu) 1999-06-28
PL183723B1 (pl) 2002-07-31
SI0733635T1 (en) 2002-06-30
ES2266719T3 (es) 2007-03-01
JPH11502535A (ja) 1999-03-02
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
CZ292688B6 (cs) 2003-11-12
EA000149B1 (ru) 1998-10-29
IS1896B (is) 2003-10-20
ATE204280T1 (de) 2001-09-15
GB2313835A (en) 1997-12-10
HK1013988A1 (en) 1999-09-17
NO974365L (no) 1997-09-22
SE9703205D0 (sv) 1997-09-05
RO118872B1 (ro) 2003-12-30
DE69630324D1 (de) 2003-11-13
ATE331719T1 (de) 2006-07-15
FI973750A (fi) 1997-09-22
FI973750A0 (fi) 1997-09-22
SI9620040B (sl) 2002-02-28
SI1095941T1 (en) 2003-12-31
EP1445259B1 (en) 2006-06-28
LT4349B (lt) 1998-05-25
KR19980703188A (ko) 1998-10-15
AT406771B (de) 2000-08-25
HU224989B1 (en) 2006-05-29
US5736541A (en) 1998-04-07
CN1065536C (zh) 2001-05-09
DK1445259T3 (da) 2006-10-16
GB9719819D0 (en) 1997-11-19
DK0733635T3 (da) 2001-10-08
GB2313835B (en) 1998-09-16
PE44897A1 (es) 1997-10-22
MY114701A (en) 2002-12-31
PL322501A1 (en) 1998-02-02
MX9707183A (es) 1997-11-29
UA44765C2 (uk) 2002-03-15
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
TR199701017T1 (xx) 1998-01-21
AP828A (en) 2000-04-28
IL117610A (en) 2001-08-26
ZA962344B (en) 1997-09-22
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
EE9700232A (et) 1998-04-15
AU706471B2 (en) 1999-06-17
TW442488B (en) 2001-06-23
AU5427996A (en) 1996-10-16
SK121897A3 (en) 1998-03-04
CZ300097A3 (en) 1997-12-17
DK1095941T3 (da) 2004-02-16
EE03489B1 (et) 2001-08-15
IL117610A0 (en) 1996-07-23
PT1095941E (pt) 2004-02-27
EP1095941A1 (en) 2001-05-02
IS4564A (is) 1997-09-22
BG62619B1 (bg) 2000-03-31
AR002719A1 (es) 1998-04-29
CA2214005A1 (en) 1996-10-03
SK284143B6 (sk) 2004-10-05
SI1445259T1 (sl) 2006-10-31
DK108997A (da) 1997-11-12
NO314663B1 (no) 2003-04-28
DE69614426D1 (de) 2001-09-20
DE19681286T1 (de) 1998-04-02
DE69630324T2 (de) 2004-07-29
LT97148A (en) 1998-01-26
CA2214005C (en) 2001-07-03
ATA902196A (de) 2000-01-15
OA10510A (en) 2002-04-24
SI9620040A (sl) 1998-06-30
EP0733635B1 (en) 2001-08-16
ES2208220T3 (es) 2004-06-16
DE69636313T2 (de) 2007-05-31
CO4650278A1 (es) 1998-09-03
NZ306110A (en) 1998-09-24
SV1996000031A (es) 1998-03-27
LU90096B1 (fr) 1997-07-22
BR9607790A (pt) 1998-07-07
EP0733635A1 (en) 1996-09-25
ZA962342B (en) 1997-09-22
YU49478B (sh) 2006-05-25
ES2159346T3 (es) 2001-10-01

Similar Documents

Publication Publication Date Title
CA2214005C (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine
AU720366B2 (en) Olanzapine dihydrate D
AU719441B2 (en) Intermediates and process for preparing olanzapine
WO1996038151A1 (en) Method for treating cognitive dysfunction
MXPA97007183A (es) Un proceso y formas de cristal de 2-metil-tieno-benzodiazepina
US6506746B2 (en) Method for treating cognitive dysfunction